Skip to content
Participate in our active studiesSubscribe to our Mailing List
AB Science
Masitinib and AB8939 – Two compounds with breakthrough mechanism of action
AB ScienceAB Science
  • Home
  • Company
    • Corporate Overview
    • Executive Commitee
    • Scientific Committee
    • Values
  • Science
    • Overview
    • Masitinib in neurodegenerative disorders
    • Masitinib in inflammatory diseases
    • AB8939 in oncology
    • Publications
  • Pipeline
    • Pipeline Overview
    • Masitinib
      • Multiple Sclerosis
      • Amyotrophic Lateral Sclerosis
      • Alzheimer’s Disease
      • Indolent Systemic Mastocytosis
      • Mast Cell Activation Syndrome
    • AB8939
  • News and Media
    • Press releases
    • In the Media
    • Webcasts
  • Investors
    • Why invest in AB Science
    • Investor Kit
    • Regulated information
      • Annual reports
      • Half-year reports
      • Social and environmental responsabilities
      • Shareholders General Meeting
      • Outstanding shares and voting rights
      • Regulated agreements
      • Board of Directors Charter
      • Information document
    • Stock Information
      • General Information
      • Analyst Coverage
    • Financial Calendar
    • Events
  • Masivet®
    • About Masivet®
    • Medical information and Pharmacovigilance
  • Careers
  • Contact
  • French
  • English
Search:
  • Home
  • Company
    • Corporate Overview
    • Executive Commitee
    • Scientific Committee
    • Values
  • Science
    • Overview
    • Masitinib in neurodegenerative disorders
    • Masitinib in inflammatory diseases
    • AB8939 in oncology
    • Publications
  • Pipeline
    • Pipeline Overview
    • Masitinib
      • Multiple Sclerosis
      • Amyotrophic Lateral Sclerosis
      • Alzheimer’s Disease
      • Indolent Systemic Mastocytosis
      • Mast Cell Activation Syndrome
    • AB8939
  • News and Media
    • Press releases
    • In the Media
    • Webcasts
  • Investors
    • Why invest in AB Science
    • Investor Kit
    • Regulated information
      • Annual reports
      • Half-year reports
      • Social and environmental responsabilities
      • Shareholders General Meeting
      • Outstanding shares and voting rights
      • Regulated agreements
      • Board of Directors Charter
      • Information document
    • Stock Information
      • General Information
      • Analyst Coverage
    • Financial Calendar
    • Events
  • Masivet®
    • About Masivet®
    • Medical information and Pharmacovigilance
  • Careers
  • Contact

Author Archives: Alexis BERNARD

You are here:
  1. Home
  2. Article author Alexis BERNARD

AB Science announces the successful completion of a EUR 1.925 million private placement

2025By Alexis BERNARDJuly 8, 2025

08/07/2025 – AB Science announces today the successful completion of a capital increase of a total gross amount of EUR 1.925 million subscribed by a limited number of investors

Masitinib receives FDA and EMA authorization for confirmatory phase 3 trial in metastatic castrate-resistant prostate cancer, with biomarker-driven patient selection targeting population most likely to benefit

2025By Alexis BERNARDJuly 4, 2025

04/07/2025 – AB Science today announced that a confirmatory phase 3 trial of masitinib in metastatic castrate resistant prostate cancer has been authorized by FDA and EMA, with a biomarker that targets patients with less advanced metastatic disease

AB Science provides an update on the renegotiation of loan repayment terms with its financial creditors

2025By Alexis BERNARDJune 30, 2025

30/06/2025 – AB Science today announced that an agreement in principle has been reached with its financial creditors to postpone by 24 months the repayment of its bank debt

New peer-reviewed data provide strong evidence supporting masitinib potential for the treatment of Alzheimer’s disease

2025By Alexis BERNARDJune 23, 2025

23/06/2025 – AB Science today announced that a new study from an independent research team based in China presents new evidences showing that masitinib offers a promising new approach to treating Alzheimer’s disease

AB Science announces issuance of a Canadian patent protecting the composition of matter of AB8939, including its use in the treatment of acute myeloid leukemia, with protection until 2036

2025By Alexis BERNARDJune 12, 2025

12/06/2025 – AB Science today announced that the patent office of Canada has  granted a patent protecting the composition of matter of AB8939, and closely related compounds, until 2036

AB Science announces EMA approval of Masivet shelf-life extension to 4 years

2025By Alexis BERNARDJune 9, 2025

09/06/2025 – AB Science today announced that the European Medicine Agency (EMA) has approved the extension of the shelf life of its veterinary medicine MASIVET® from 36 months to 48 months

AB Science announces the settlement delivery of its latest capital increase for €1.8 million

2025By Alexis BERNARDMay 23, 2025

23/05/2025 – AB Science today announces the settlement and delivery of its capital increase announced on May 20, 2025 for an amount of €1.8 million, subscribed by a limited number of investors

AB Science announces the successful completion of a EUR 1.8 million private placement

2025By Alexis BERNARDMay 20, 2025

20/05/2025 – AB Science announces today the successful completion of a capital increase of a total gross amount of EUR 1.8 million subscribed by a limited number of investors

AB Science receives Chinese patent protecting masitinib in the treatment of Covid-19 until 2041

2025By Alexis BERNARDMay 19, 2025

19/05/2025 – AB Science today announced that the Chinese Patent Office has issued a patent relating to methods of treating severe acute respiratory syndrome coronavirus 2 infection causing COVID-19

AB Science reports a new publication in the scientific journal PLOS One

2025By Alexis BERNARDMay 15, 2025

15/05/2025 – AB Science today reports a new publication in the scientific journal PLOS One, showing promising neuroprotective effects of masitinib

→12345…
678910111213141516171819202122232425
26→
AB Science
© AB Science – All right reserved
Go to Top